ArticleJournal of medical biochemistry2025
Combination of prostate cancer antigen 3 (PCA3), sarcosine, glypican-1 (GPC1), urokinase plasminogen activator receptor (uPAR), and thymidine kinase 1 (TK1), and T2WI and DWI radiomics model for distinguishing benign prostatic hyperplasia, prostate cancer, and prostatitis.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human biomarker navigator.iMeta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To measure the diagnostic value of T2WI and DWI radiomics model, combined with advanced biomarkers, in distinguishing benign prostatic hyperplasia (BPH), prostate cancer (PCa) and prostatitis. Methods: A total of 90 patients with prostate diseases were selected from our hospital from January 2022 to January 2024. All patients underwent T2WI and DWI MRI examinations. Regions of interest (ROI) were delineated, and imaging features were extracted using radiomics analysis. In addition, novel biomarkers, including Prostate Cancer Antigen 3 (PCA3), Sarcosine, Glypican-1 (GPC1), Urokinase Plasminogen Activator Receptor (uPAR), and Thymidine Kinase 1 (TK1), were analysed for their diagnostic significance. Feature selection was performed using LASSO regression, and a random forest model was established for classification. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of the T2WI and DWI radiomics model with and without biomarker integration. Results: Among the 90 patients with prostate diseases, 50 cases were PCa, 20 cases of prostatitis and 20 cases of BPH were detected by biopsy. The PI-RADS v2 score in the PCa group presented elevation relative to those in the BPH and prostatitis groups (P<0.01). The ADC values in the PCa group were reduced relative to those in the BPH and prostatitis groups (P<0.01). The integration of biomarkers with radiomics analysis led to improved diagnostic performance. The AUC value, sensitivity, and specificity of the T2WI and DWI radiomics model were higher relative to those of PI-RADS V2. Conclusions: The T2WI and DWI radiomics model, when combined with novel biomarkers, enhances the accuracy of distinguishing PCa, BPH, and prostatitis. This approach may provide an advanced diagnostic tool for personalised prostate disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.